Submitted by Anonymous (not verified) on 18 November 2025 - 13:30
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 4, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Omlyclo, omalizumab, Date of authorisation: 16/05/2024, Revision: 4, Status: Authorised